CenterBook Partners’s Ascendis Pharma A/S ASND Stock Holding History

CenterBook Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$834K	Sell	3,126 -2,887	-48%	-$674K	0.04%	395
2026 Q1	$1.38M	Buy	+6,013	New	+$1.35M	0.07%	299
2024 Q3	–	Sell	-10,905	Closed	-$1.49M	–	451
2024 Q2	$1.49M	Buy	+10,905	New	+$1.48M	0.09%	296
2024 Q1	–	Sell	-5,207	Closed	-$656K	–	381
2023 Q4	$656K	Sell	5,207 -4,317	-45%	-$430K	0.08%	300
2023 Q3	$892K	Sell	9,524 -13,615	-59%	-$1.27M	0.11%	260
2023 Q2	$2.07M	Buy	23,139 +16,864	+269%	+$1.47M	0.26%	131
2023 Q1	$673K	Sell	6,275 -2,915	-32%	-$333K	0.1%	285
2022 Q4	$1.12M	Buy	9,190 +6,636	+260%	+$770K	0.18%	184
2022 Q3	$264K	Sell	2,554 -1,549	-38%	-$147K	0.05%	349
2022 Q2	$381K	Buy	+4,103	New	+$387K	0.08%	300

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

CenterBook Partners's ASND Position: Q2 2026 in Review

CenterBook Partners reduced its Ascendis Pharma A/S (ASND) stake by 48% in Q2 2026, selling an estimated $674K and leaving 3,126 shares worth $834K. The position accounts for 0.04% of the portfolio, ranked #395.

CenterBook Partners first reported a position in ASND in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.07M in Q2 2023. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

CenterBook Partners held 3,126 shares of Ascendis Pharma A/S worth $834K as of Q2 2026.
CenterBook Partners sold 2,887 Ascendis Pharma A/S shares in Q2 2026, an estimated $674K.
Ascendis Pharma A/S made up 0.04% of CenterBook Partners's portfolio in Q2 2026, its #395 holding.
CenterBook Partners first reported a position in Ascendis Pharma A/S in Q2 2022 and has held it in 10 quarters since.
CenterBook Partners's Ascendis Pharma A/S position peaked at $2.07M in Q2 2023.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.